Sjorgren's syndrome flare / 1 day after 2nd dose; Lupus flare / 3 days after 2nd dose; Sjogren's syndrome flare, Lupus flare, Alopecia flare; body aches; fatigue; malaise; joint pain; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 15Feb2021 (Lot number: EL9264) at the age of 38 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Lupus (SLE)", start date: 1991 (ongoing), notes: Illness started at age 8, diagnosed at age 15.; "Lupus (DLE)", start date: 1994 (ongoing), notes: Illness started at age 8, diagnosed at age 15.; "Sjogren's", start date: 1995 (ongoing), notes: Illness started at age 8, diagnosed at age 15.; "Alopecia", start date: 1995 (ongoing), notes: Illness started at age 8, diagnosed at age 15. Family history included: "myasthenia gravis" (unspecified if ongoing), notes: Great grandmother myasthenia gravis, sister migraines, systemic lupus/nephritis, Raynaud's syndrome; "migraines" (unspecified if ongoing), notes: Great grandmother myasthenia gravis, sister migraines, systemic lupus/nephritis, Raynaud's syndrome; "systemic lupus" (unspecified if ongoing), notes: Great grandmother myasthenia gravis, sister migraines, systemic lupus/nephritis, Raynaud's syndrome; "nephritis" (unspecified if ongoing), notes: Great grandmother myasthenia gravis, sister migraines, systemic lupus/nephritis, Raynaud's syndrome; "Raynaud's syndrome" (unspecified if ongoing), notes: Great grandmother myasthenia gravis, sister migraines, systemic lupus/nephritis, Raynaud's syndrome. Concomitant medication(s) included: BUSPIRONE, start date: Dec2020 (ongoing); FAMOTIDINE, start date: Oct2020 (ongoing). Vaccination history included: Bnt162b2 (First Dose, lot number: EL8982, Route: Injected, Anatomical location: Right arm, No.of previous doses: 0), administration date: 25Jan2021, when the patient was 38 years old, for Covid-19 Immunization, reaction(s): "slight uptick in Sjogren's syndrome and Discoid Lupus symptoms. Her lesion opened and oozed, and dry eyes and dry mouth increased significantly", "slight uptick in Sjogren's syndrome and Discoid Lupus symptoms. Her lesion opened and oozed, and dry eyes and dry mouth increased significantly", "slight uptick in Sjogren's syndrome and Discoid Lupus symptoms. Her lesion opened and oozed, and dry eyes and dry mouth increased significantly", "vision problems", "dry eye", "lost about 25% of my hair due to alopecia areata". The following information was reported: SJOGREN'S SYNDROME (medically significant) with onset Feb2021, outcome "not recovered", described as "Sjorgren's syndrome flare / 1 day after 2nd dose"; SYSTEMIC LUPUS ERYTHEMATOSUS (medically significant) with onset Feb2021, outcome "not recovered", described as "Lupus flare / 3 days after 2nd dose"; CONDITION AGGRAVATED (non-serious) with onset Feb2021, outcome "not recovered", described as "Sjogren's syndrome flare, Lupus flare, Alopecia flare"; PAIN (non-serious) with onset 2021, outcome "unknown", described as "body aches"; FATIGUE (non-serious) with onset 2021, outcome "unknown", described as "fatigue"; MALAISE (non-serious) with onset 2021, outcome "unknown", described as "malaise"; ARTHRALGIA (non-serious) with onset 2021, outcome "unknown", described as "joint pain". The events "sjorgren's syndrome flare / 1 day after 2nd dose", "lupus flare / 3 days after 2nd dose" and "sjogren's syndrome flare, lupus flare, alopecia flare" were evaluated at the physician office visit. Therapeutic measures were taken as a result of sjogren's syndrome, systemic lupus erythematosus, condition aggravated, pain, fatigue, malaise, arthralgia. The patient experienced Sjorgren's syndrome flare one day after second dose, Lupus flare three days after second dose and Alopecia flare one week after second dose. The patient saw rheumatologist after increase in symptoms. In Feb2021 the patient took Began with prednisone 20 mg a day tapered off to 5 mg/day. Benlysta and prednisone seem to have halted fare. The vaccination facility type was hospital.  No follow-up attempts are possible. No further information is expected.